NCT06147622View on ClinicalTrials.gov

A Study to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 23, 2024

Primary Completion Date

July 31, 2024

Study Completion Date

December 31, 2024

Conditions
Alcohol Use Disorder
Interventions
DRUG

Prazosin + cyproheptadine

Subjects will receive prazosin + cyproheptadine on day 1 of period 1 or on day 1 of period 2 depending on randomization.

DRUG

KT110

Subjects will receive KT110 on day 1 of period 1 or on day 1 of period 2 depending on randomization.

Trial Locations (1)

38610

Eurofins Optimed, Gières

Sponsors
All Listed Sponsors
lead

Kinnov Therapeutics

OTHER